Should future triglyceride-lowering therapy trials enroll patients across a wider range of triglyceride levels?
Future clinical trials for triglyceride-lowering therapies should consider enrolling patients across a wider range of triglyceride levels to better understand cardiovascular risk.
Individuals with mild-to-moderate hypertriglyceridaemia may not express the same magnitude of cardiovascular risk as that observed across the full range of plasma triglycerides. Future triglyceride-lowering therapy trials may want to consider enrolment across a wider range of triglyceride levels if there is no prior history of pancreatitis nor excessive alcohol intake.
Nordestgaard et al. (Wed,) studied this question.